These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 38673829)

  • 1. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
    Tian J; Quek C
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.
    Carey AE; Weeraratna AT
    Pharmacol Ther; 2024 Oct; 262():108698. PubMed ID: 39098769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.
    He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S
    Front Immunol; 2024; 15():1435187. PubMed ID: 39026661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
    Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
    Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
    Hossain SM; Ly K; Sung YJ; Braithwaite A; Li K
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
    Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.
    Holmberg CJ; Ny L; Hieken TJ; Block MS; Carr MJ; Sondak VK; Örtenwall C; Katsarelias D; Dimitriou F; Menzies AM; Saw RP; Rogiers A; Straker RJ; Karakousis G; Applewaite R; Pallan L; Han D; Vetto JT; Gyorki DE; Tie EN; Vitale MG; Ascierto PA; Dummer R; Cohen J; Hui JY; Schachter J; Asher N; Helgadottir H; Chai H; Kroon H; Coventry B; Rothermel LD; Sun J; Carlino MS; Duncan Z; Broman K; Weber J; Lee AY; Berman RS; Teras J; Ollila DW; Long GV; Zager JS; van Akkooi A; Olofsson Bagge R
    Eur J Cancer; 2022 Jul; 169():210-222. PubMed ID: 35644725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients.
    Dufau C; Genais M; Mucher E; Jung B; Garcia V; Montfort A; Tosolini M; Clarke CJ; Medin JA; Levade T; Delord JP; Meyer N; Pancaldi V; Andrieu-Abadie N; Ségui B
    Front Immunol; 2024; 15():1421432. PubMed ID: 39136013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.
    Hossain SM; Carpenter C; Eccles MR
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
    Nebhan CA; Johnson DB
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):137-145. PubMed ID: 31997676
    [No Abstract]   [Full Text] [Related]  

  • 18. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
    Schlenker R; Schwalie PC; Dettling S; Huesser T; Irmisch A; Mariani M; Martínez Gómez JM; Ribeiro A; Limani F; Herter S; Yángüez E; Hoves S; Somandin J; Siebourg-Polster J; Kam-Thong T; de Matos IG; Umana P; Dummer R; Levesque MP; Bacac M
    Med; 2024 Jul; 5(7):759-779.e7. PubMed ID: 38593812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
    Davar D; Tarhini AA; Kirkwood JM
    Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.